Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 856

1.

Clinicopathologic analysis of upper urinary tract carcinoma with variant histology.

Rolim I, Henriques V, Rolim N, Blanca A, Marques RC, Volavšek M, Carvalho I, Montironi R, Cimadamore A, Raspollini MR, Cheng L, Lopez-Beltran A.

Virchows Arch. 2020 Jan 16. doi: 10.1007/s00428-020-02745-4. [Epub ahead of print]

PMID:
31950242
2.

Molecular diagnostics in uro-oncology.

Montironi R, Cheng L, Cimadamore A, Lopez-Beltran A.

Expert Rev Mol Diagn. 2020 Jan 14. doi: 10.1080/14737159.2020.1715799. [Epub ahead of print] No abstract available.

PMID:
31933387
3.

PD-L1 assessment in urothelial carcinoma: a practical approach.

Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T.

Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24. Review.

4.

Overview of potential determinants of radical prostatectomy versus radiation therapy in management of clinically localized prostate cancer: results from an Italian, prospective, observational study (the Pros-IT CNR study).

Antonelli A, Palumbo C, Noale M, Artibani W, Bassi P, Bertoni F, Bracarda S, Bruni A, Corvò R, Gacci M, Magrini SM, Montironi R, Porreca A, Tubaro A, Zagonel V, Maggi S; and the Pros-IT CNR study group.

Minerva Urol Nefrol. 2020 Jan 7. doi: 10.23736/S0393-2249.19.03637-3. [Epub ahead of print]

PMID:
31920063
5.

Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.

Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R.

Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0745. [Epub ahead of print] No abstract available.

PMID:
31916449
6.

Ex vivo fluorescence confocal microscopy: prostatic and periprostatic tissues atlas and evaluation of the learning curve.

Bertoni L, Puliatti S, Reggiani Bonetti L, Maiorana A, Eissa A, Azzoni P, Bevilacqua L, Spandri V, Kaleci S, Zoeir A, Sighinolfi MC, Micali S, Bianchi G, Pellacani G, Rocco B, Montironi R.

Virchows Arch. 2020 Jan 6. doi: 10.1007/s00428-019-02738-y. [Epub ahead of print]

PMID:
31907606
7.

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N.

Cancers (Basel). 2019 Dec 30;12(1). pii: E84. doi: 10.3390/cancers12010084.

8.

Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.

Gandhi JS, Smith SC, Paner GP, McKenney JK, Sekhri R, Osunkoya AO, Baras AS, DeMarzo AM, Cheville JC, Rafael JE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Sirohi D, Kaushal S, Sangoi A, Robinson BD, Kweldam CF, Humphrey PA, Hansel DE, Schultz L, Magi-Galluzzi C, Przybycin CG, Shah RB, Mehra R, Kunju LP, Aron M, Kryvenko ON, Kench JG, Kuroda N, Tavora F, van der Kwast T, Grignon DJ, Epstein JI, Reuter VE, Amin MB.

Am J Surg Pathol. 2019 Dec 23. doi: 10.1097/PAS.0000000000001417. [Epub ahead of print]

PMID:
31876580
9.

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.

Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Battelli N, Montironi R.

Expert Rev Cardiovasc Ther. 2019 Dec;17(12):917-927. doi: 10.1080/14779072.2019.1704626. Epub 2019 Dec 19.

PMID:
31829045
10.

Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.

Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, Cimadamore A, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R.

Expert Rev Mol Diagn. 2019 Dec 11:1-13. doi: 10.1080/14737159.2020.1699791. [Epub ahead of print]

PMID:
31795775
11.

The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.

Aurilio G, Piva F, Santoni M, Cimadamore A, Sorgentoni G, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R.

Int J Mol Sci. 2019 Nov 13;20(22). pii: E5683. doi: 10.3390/ijms20225683. Review.

12.

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F.

Eur Urol. 2019 Nov 8. pii: S0302-2838(19)30825-5. doi: 10.1016/j.eururo.2019.10.026. [Epub ahead of print]

PMID:
31708296
13.

Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).

Buglione M, Noale M, Bruni A, Antonelli A, Bertoni F, Corvo' R, Ricardi U, Borghetti P, Maddalo M, Simeone C, Mazzeo E, Porreca A, Serni S, Bassi P, Gacci M, Mirone V, Montironi R, Tubaro A, Berruti A, Conti GN, Maggi S, Magrini SM, Triggiani L; Pros-IT CNR study group.

PLoS One. 2019 Nov 1;14(11):e0224151. doi: 10.1371/journal.pone.0224151. eCollection 2019.

14.

Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.

Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A.

Immunotherapy. 2019 Dec;11(17):1507-1521. doi: 10.2217/imt-2019-0115. Epub 2019 Oct 30.

PMID:
31663411
15.

Liquid biopsies in renal cell carcinoma with focus on epigenome analysis.

Cimadamore A, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Ann Transl Med. 2019 Sep;7(Suppl 6):S194. doi: 10.21037/atm.2019.07.30. No abstract available.

16.

An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.

Mollica V, Di Nunno V, Santoni M, Cimadamore A, Scarpelli M, Lopez-Beltran A, Cheng L, Mariani C, Battelli N, Montironi R, Massari F.

Expert Rev Mol Diagn. 2019 Oct 29:1-11. doi: 10.1080/14737159.2019.1684265. [Epub ahead of print]

PMID:
31640441
17.

Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma.

Santoni M, Heng DY, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R, Cimadamore A, Scarpelli M, Zaghloul MS, Battelli N, Montironi R.

Curr Drug Targets. 2019 Oct 17. doi: 10.2174/1389450120666191017113051. [Epub ahead of print]

PMID:
31625471
18.

Liquid biopsy in the clinical management of bladder cancer: current status and future developments.

Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, Cimadamore A, Cheng L.

Expert Rev Mol Diagn. 2019 Oct 17:1-10. doi: 10.1080/14737159.2019.1680284. [Epub ahead of print]

PMID:
31608720
19.

Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples.

Volavšek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A.

Virchows Arch. 2019 Dec;475(6):735-744. doi: 10.1007/s00428-019-02666-x. Epub 2019 Oct 7.

PMID:
31588959
20.

Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.

Di Nunno V, Massari F, Mollica V, Cimadamore A, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Ann Transl Med. 2019 Jul;7(Suppl 3):S137. doi: 10.21037/atm.2019.06.06. No abstract available.

21.

Prostate cancer pathology: What has changed in the last 5 years.

Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R.

Urologia. 2019 Sep 23:391560319876821. doi: 10.1177/0391560319876821. [Epub ahead of print]

PMID:
31545701
22.

Liquid biopsies in urological cancers: what we need to know before starting using them.

Franceschini T, Giunchi F, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Fiorentino M.

Expert Rev Mol Diagn. 2019 Sep 11:1-5. doi: 10.1080/14737159.2019.1665508. [Epub ahead of print] No abstract available.

PMID:
31509027
23.

Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.

Cimadamore A, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Moch H.

Expert Rev Mol Diagn. 2019 Sep 11:1-10. doi: 10.1080/14737159.2019.1665510. [Epub ahead of print]

PMID:
31498685
24.

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers.

Santoni M, Cimadamore A, Massari F, Piva F, Aurilio G, Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N, Cheng L, Lopez-Beltran A, Montironi R.

Cancers (Basel). 2019 Aug 22;11(9). pii: E1225. doi: 10.3390/cancers11091225. Review.

25.

Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule.

Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, Cimadamore A, Lopez-Beltran A.

Hum Pathol. 2019 Nov;93:6-15. doi: 10.1016/j.humpath.2019.08.012. Epub 2019 Aug 21.

PMID:
31442520
26.

Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of Large-format Histology.

Cimadamore A, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R.

Eur Urol. 2019 Aug 13. pii: S0302-2838(19)30608-6. doi: 10.1016/j.eururo.2019.07.047. [Epub ahead of print] No abstract available.

PMID:
31420247
27.

Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution.

Bravi CA, Vertosick E, Tin A, Scuderi S, Fallara G, Rosiello G, Mazzone E, Bandini M, Gandaglia G, Fossati N, Freschi M, Montironi R, Briganti A, Montorsi F, Vickers A.

Eur Urol Oncol. 2018 Nov 24. pii: S2588-9311(18)30188-3. doi: 10.1016/j.euo.2018.10.007. [Epub ahead of print]

PMID:
31411978
28.

A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss.

Di Nunno V, Mollica V, Brunelli M, Gatto L, Schiavina R, Fiorentino M, Santoni M, Montironi R, Caliò A, Eccher A, Milella M, Martignoni G, Brunocilla E, Massari F.

Mol Diagn Ther. 2019 Oct;23(5):569-577. doi: 10.1007/s40291-019-00414-0. Review.

PMID:
31332726
29.

Editorial Comment.

Montironi R, Scarpelli M.

J Urol. 2019 Oct;202(4):715-716. doi: 10.1097/01.JU.0000576624.92404.c4. Epub 2019 Sep 6. No abstract available.

PMID:
31282273
30.

Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM).

Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Pappagallo GL, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, Gori S, Cartenì G.

Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.

PMID:
31264522
31.

Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.

Rebola J, Aguiar P, Blanca A, Montironi R, Cimadamore A, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A.

Virchows Arch. 2019 Oct;475(4):445-455. doi: 10.1007/s00428-019-02593-x. Epub 2019 Jun 25.

PMID:
31240474
32.

Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer.

Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A.

APMIS. 2019 Aug;127(8):545-553. doi: 10.1111/apm.12973.

PMID:
31231851
33.

Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.

Gevaert T, Cimadamore A, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R.

Future Oncol. 2019 Jul;15(19):2199-2202. doi: 10.2217/fon-2019-0217. Epub 2019 Jun 19. No abstract available.

PMID:
31213082
34.

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.

Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F.

Cancers (Basel). 2019 Jun 14;11(6). pii: E830. doi: 10.3390/cancers11060830. Review.

35.

MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia.

Magers MJ, Iczkowski KA, Montironi R, Grignon DJ, Zhang S, Williamson SR, Yang X, Wang M, Osunkoya AO, Lopez-Beltran A, Hes O, Eble JN, Cheng L.

Mod Pathol. 2019 Nov;32(11):1666-1674. doi: 10.1038/s41379-019-0297-6. Epub 2019 Jun 12.

PMID:
31189999
36.

Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?

Montironi R, Cheng L, Scarpelli M, Cimadamore A, Montorsi F, Lopez-Beltran A.

Eur Urol. 2019 Sep;76(3):e69-e72. doi: 10.1016/j.eururo.2019.05.035. Epub 2019 Jun 6. No abstract available.

PMID:
31176624
37.

BAP1 in solid tumors.

Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F.

Future Oncol. 2019 Jun;15(18):2151-2162. doi: 10.2217/fon-2018-0915. Epub 2019 Jun 4. Review.

PMID:
31159579
38.

Editorial: Emerging Biomarkers in Genitourinary Tumors.

Montironi R, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L.

Front Oncol. 2019 Apr 26;9:326. doi: 10.3389/fonc.2019.00326. eCollection 2019. No abstract available.

39.

Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.

Montironi R, Zhou M, Magi-Galluzzi C, Epstein JI.

Eur Urol Oncol. 2018 May;1(1):21-28. doi: 10.1016/j.euo.2018.03.013. Epub 2018 May 15. Review.

PMID:
31100224
40.

Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges.

Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R.

Front Oncol. 2019 Apr 5;9:228. doi: 10.3389/fonc.2019.00228. eCollection 2019. No abstract available.

41.

Should We Perform Multiparametric Magnetic Resonance Imaging of the Bladder Before Transurethral Resection of Bladder? Time to Reconsider the Rules.

Panebianco V, Narumi Y, Barchetti G, Montironi R, Catto JWF.

Eur Urol. 2019 Jul;76(1):57-58. doi: 10.1016/j.eururo.2019.03.046. Epub 2019 Apr 15. No abstract available.

PMID:
31000355
42.

Microbiome and Cancers, With Focus on Genitourinary Tumors.

Cimadamore A, Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M.

Front Oncol. 2019 Mar 26;9:178. doi: 10.3389/fonc.2019.00178. eCollection 2019. No abstract available.

43.

Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution.

Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F.

Clin Drug Investig. 2019 Jun;39(6):503-519. doi: 10.1007/s40261-019-00773-w. Review.

PMID:
30937824
44.

The Human Microbiota and Prostate Cancer: Friend or Foe?

Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G.

Cancers (Basel). 2019 Mar 31;11(4). pii: E459. doi: 10.3390/cancers11040459. Review.

45.

Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients.

Rocco B, Sighinolfi MC, Sandri M, Eissa A, Elsherbiny A, Zoeir A, Tadzia H, Palayapalayam H, Kameh D, Coelho R, Puliatti S, Zuccolotto P, Montironi R, Wiklund P, Micali S, Bianchi G, Patel V.

Urology. 2019 Jul;129:8-20. doi: 10.1016/j.urology.2019.03.019. Epub 2019 Mar 28. Review.

PMID:
30928608
46.

Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate.

Cheng L, Montironi R, Davidson DD, Wang M, Lopez-Beltran A, Zhang S.

Mol Carcinog. 2019 Jul;58(7):1272-1278. doi: 10.1002/mc.23009. Epub 2019 Mar 28.

PMID:
30920030
47.

Ex vivo fluorescence confocal microscopy: the first application for real-time pathological examination of prostatic tissue.

Puliatti S, Bertoni L, Pirola GM, Azzoni P, Bevilacqua L, Eissa A, Elsherbiny A, Sighinolfi MC, Chester J, Kaleci S, Rocco B, Micali S, Bagni I, Bonetti LR, Maiorana A, Malvehy J, Longo C, Montironi R, Bianchi G, Pellacani G.

BJU Int. 2019 Sep;124(3):469-476. doi: 10.1111/bju.14754. Epub 2019 Apr 17.

PMID:
30908852
48.

Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer.

Cimadamore A, Palagonia E, Piccinni P, Misericordia M, Galosi AB, Montironi R.

Urologia. 2019 Feb;86(1):35-38. doi: 10.1177/0391560319834494. Epub 2019 Feb 27.

PMID:
30808261
49.

Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.

Cimadamore A, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R.

Curr Drug Metab. 2019;20(4):305-312. doi: 10.2174/1389200220666190225124352.

PMID:
30799789
50.

Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy.

Cimadamore A, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R.

Cancers (Basel). 2019 Feb 7;11(2). pii: E196. doi: 10.3390/cancers11020196. Review.

Supplemental Content

Loading ...
Support Center